Health
A Call for Nuance in Cardioprotection With Early Breast Cancer Therapy – MedPage Today
Longer-term PRADA trial results weigh in for low-risk group
For low-risk breast cancer patients getting potentially cardiotoxic treatment, candesartan’s (Atacand) short-term protection of cardiac function faded longer term in the PRADA trial.
Left ventricular ejection fraction (LVEF) declined a similar amount from baseline to 23 months post-randomization for patients given candesartan during adjuvant breast cancer treatment versus those who were not (1.7 vs 1.8 percentage points, P=0.91), reported Siri Heck, MD, PhD, of Akershus University Hospital in Lørenskog,…
-
Noosa News18 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News16 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
Noosa News22 hours agoBrisbane Broncos star Reece Walsh says punching friend in face ‘not a good look’
-
General14 hours agoDairy farmers devastated by floods across parts of New South Wales